ClinicalTrials.gg
RecruitingNCT05424003Updated Jun 4, 2026

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

A Phase 2 interventional study of Semaglutide Pen Injector and Placebo in NAFLD, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Virginia · Phase 2, Interventional, and Prevention

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 8 under way, 1 of them phase 3. Semaglutide · Non-alcoholic Fatty Liver Disease.

Planned enrollment
15th of 16
50 · median 88
Started
2024
the only one that year
Phase 2
8 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, this one is the 15th largest by planned enrollment, is the only one that started in 2024, is one of 8 in phase 2, and was the 12th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

4 of the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, or all of them as a file.
02

Study summary

In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.

Read the detailed description

Weight gain following LT is common and a risk for cardiovascular disease and development of NAFLD. Developing NAFLD following LT can lead to patients developing scar tissue in the graft (transplanted liver), and graft-cirrhosis. These events can limit the benefit of the transplanted liver graft and reduce the benefit of LT as a therapy. Current weight management strategies have not been successful at the prevention of these events in most patients. This highlights a substantial unmet need for effective treatment to prevent or reduce post-LT weight gain and highlight the importance of new treatment strategies for reducing illness, death, and healthcare cost associated with post-LT weight gain.

The purpose of this research study is to test the safety, tolerability, and effectiveness of semaglutide when used to prevent weight gain after liver transplant. Semaglutide is a drug that has been approved by the U. S. Food and Drug Administration (FDA) for treatment of obesity and Type 2 Diabetes.

Semaglutide, has shown to be effective for not only weight loss but also long-term weight maintenance. Semaglutide has also shown to be helpful in treatment of nonalcoholic steatohepatitis (NASH) in the non-transplant population. This medication also is used to control blood sugar and prevent cardiovascular disease, which contributes to poor outcomes in LT recipients. Thus, the purpose of the present study is to determine if use of semaglutide early after LT can (1) reduce weight gain and (2) prevent development of NAFLD following LT.

03

Conditions studied

  • NAFLD

Keywords

  • Liver Transplant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18-75 years who received LT for any indication (i.e. NASH, , alcohol-induced cirrhosis, hepatitis, etc.)
  • Liver transplant surgery within 8-24 weeks prior to randomization
  • Fasting glucose > 125 mg/dL or presence of diabetes (≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c >5.7%)
  • Ability to provide
  • Discharged from the hospital following LT surgery
  • Tolerating diet
  • Normal graft function* (determined by treating hepatologist/surgeon based on clinical status and hepatic panel)
  • Stable according the VCU (Virginia Commonwealth University) post-LT protocols ** (i.e. calcineurin inhibitors + mycophenolate)
  • Eligible female patients will be (1) non-pregnant, evidenced by a negative urine pregnancy test, (2) non-lactating, (3)surgically sterile or , or they will agree to continue to use an accepted method of during the study

Exclusion criteria

Exclusion Criteria:

  • ≤ 27kg/m2
  • (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
  • Type 1 diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
  • History of gastroparesis
  • Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2
  • History of pancreatitis
  • History of active post- LT with the exception of non-melanoma skin cancers
  • History of uncontrolled or unstable diabetic retinopathy or maculopathy
  • Acute cellular rejection
  • Hepatic artery thrombosis
  • Medical non-compliance
  • Active treatment with GLP (glucagon-like peptide)-1RA (receptor agonist) or SGLT (sodium-glucose cotransporter)-2 inhibitors at time of screening
  • History of to semaglutide or its
  • Women who are nursing, pregnant, or planning to become pregnant during the study, or are not using adequate measures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Semaglutide administered subcutaneously (under the skin) once weekly. There will be a 20 week lead in period of dose escalation before reaching the target dose of 2.4mg weekly. Semaglutide will then be administered at the maximum tolerated dose for 52 weeks.

    Drug: Semaglutide Pen Injector

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously (under the skin) once weekly.

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose

    Also known as: Wegovy

  • DrugPlacebo

    Placebo solution injected weekly for 72 weeks

06

What researchers measure

Primary outcomes

  1. Change in weight

    Weight measured in kilograms

    Time frame: Baseline to week 72

Secondary outcomes

  1. Development of NAFLD

    Number of participant who develop NAFLD by the end of treatment will be measured via MRI-PDFF (MRI-Proton Density Fat Fraction). A value of \>5.2% will be considered the threshold for development of NAFLD following LT.

    Time frame: Week 72

  2. Change in adiposity

    Fat distribution of the body body (body composition) will be assessed via MRI (i.e. visceral adipose tissue, abdominal subcutaneous tissue, fat free muscle volume, and muscle fat infiltration, epicardial fat). Means of delta body composition measures after 72 weeks will be compared between the two arms.

    Time frame: Baseline to week 72

  3. Change in insulin resistance

    Frequently Sampled IV Glucose Tolerance Test (FSIVGTT) will be used to measure insulin resistance

    Time frame: Baseline to week 72

  4. Change in inflammation - C-reactive protein (CRP)

    Level of CRP will be assessed using a standard blood test.

    Time frame: Baseline to week 72

  5. Change in inflammation - adiponectin

    Level of adiponectin will be assessed using a standard blood test.

    Time frame: Baseline to week 72

  6. Change in liver fibrosis markers

    Fibrosis-4 (FIB-4) Index for Liver Fibrosis and NAFLD Fibrosis Score (NFS) will be assessed using a standard blood test.

    Time frame: Baseline to week 72

  7. Change in serum lipid profile

    Cardiovascular risk factors will be assessed using a standard lipid panel blood test.

    Time frame: Baseline to week 72

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2026, 29 months after the start.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 21, 2022
StartActual
Feb 22, 2024
Primary completionEst.
Aug 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05424003
Collaborators
Novo Nordisk A/S
Responsible party
Mohammad Siddiqui (Professor of Medicine, University of Virginia) — Principal investigator
First posted
Jun 21, 2022
Start date
Feb 22, 2024
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Sherry Boyett, RN
Contact
sherry.boyett@vcuhealth.org
804-828-5434
Mohammad S Siddiqui, MD
Contact
mohammad.siddiqui@vcuhealth.org
Mohammad S Siddiqui, MD
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion